Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigecycline vs Imipenem/Cilastatin in Hospital-Acquired Pneumonia
NCT00707239Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2008
- Primary completion
- Jun 2011
- Modality
- Orthosteric Ligands
- Countries
- 14
01
Overview
A Phase 2 trial of tigecycline in hospital-acquired pneumonia (HAP), sponsored by Pfizer. Started Dec 2008; status: terminated.
02
Drugs
tigecycline
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00707239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707239.